Genentech, Adaptive winding down 2018 pact: Deals Report

Amid a quiet August for dealmaking, Adaptive disclosed that a T cell therapy partnership with Genentech is coming to an end after about seven years.

Early Monday, Adaptive Biotechnologies Corp. (NASDAQ:ADPT) revealed in a regulatory filing that its 2018 agreement with the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) is winding down, with an official end date of Feb. 9, 2026...